Electrophysiological effects of a new antiarrhythmic agent, flecainide, on the intact canine heart.
The cardiac electrophysiology of flecainide a new antiarrhythmic agent, was studied in open-chested dogs. At plasma concentrations of 0.4 to 0.7 microgram/ml, flecainide significantly prolonged atrioventricular (AV) conduction. At plasma concentrations greater than 6.5 micrograms/ml, flecainide caused delay throughout the conduction system (77--240%). Low plasma levels of flecainide caused slight prolongation in atrial effective refractory period and AV nodal functional and relative refractory periods. At flecainide levels of 0.7 microgram/ml, ventricular response during atrial fibrillation was significantly slowed. The effects of flecainide on AV nodal and infranodal conduction and refractoriness were significantly enhanced by d,1-propranolol (0.5 mg/kg) but were unaffected by ouabain (0.01 mg/kg). The ventricular fibrillation threshold of supraventricular beats and ventricular premature beats increased with increasing plasma flecainide concentration (122% at 9.3 micrograms/ml and 172% at 1.3 micrograms/ml, respectively). Flecainide slowed ectopic atrial and ventricular pacemakers without affecting sinusor junctional pacemakers.
D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology*; D001281:Atrial Fibrillation / Q000503:physiopathology; D002304:Cardiac Pacing, Artificial; D004285:Dogs; D004594:Electrophysiology; D005424:Flecainide; D006321:Heart / Q000187:drug effects*; D006329:Heart Conduction System / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D008297:Male; D010880:Piperidines / Q000494:pharmacology*; D011433:Propranolol / Q000494:pharmacology; D014693:Ventricular Fibrillation / Q000503:physiopathology
D000889:Anti-Arrhythmia Agents; D010880:Piperidines; D011433:Propranolol; D005424:Flecainide